Skip to content
Open access · OA via Europe PMC

Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.

Aygüneş-Jafari D, Düzgün Z.

Biomedicines · 2026

Abstract

<b>Background/Objectives:</b> Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease, and cellular senescence(definition) is a tractable therapeutic target; yet prioritizing credible repurposing candidates is difficult because bulk-tissue senescence signals are weak, single-dataset analyses are unstable, and transcriptome-reversal screens overstate novelty. The objective was to build a senescence-anchored, multi-evidence computational prioritization of repurposing candidates for DKD entirely from open data. <b>Methods:</b> Per-sample senescence activity was quantified by single-sample gene set enrichment across three DKD kidney cohorts, and consensus signatures were reversed against 45,956 LINCS L1000 signatures. Candidates were ranked by reversal strength, mechanism, ChEMBL stage, and ClinicalTrials.gov novelty, then assessed for robustness by senotherapeutic enrichment, an external senolytic benchmark, leave-one-cohort-out analysis, drug-target Mendelian randomization, and single-nucleus profiling. <b>Results:</b> Senescence activity was consistently elevated in DKD across all three cohorts, with moderate-to-large effect sizes (rank-biserial 0.32-0.78). Reversal recovered established senotherapeutic classes and nominated the approved JAK inhibitor fedratinib (within the same class, baricitinib reduced albuminuria in a Phase 2 DKD trial); curated senolytics(definition) were modestly separated from negatives (AUROC 0.62, 95% CI 0.52-0.72). Filtering yielded 867 mechanism-annotated compounds robust to cohort removal. Drug-target Mendelian randomization was inconclusive, and single-nucleus profiling highlighted endothelial activation rather than a stable senescent compartment. <b>Conclusions:</b> The result is an externally benchmarked, novelty-annotated senotherapeutic candidate map, offered as convergent confirmation of repurposable mechanisms rather than a claim of new drug classes.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.3390/biomedicines14102286
Canonical
link ↗
Fetched
2026-10-31 MST

Cite this

APA
D, A., &amp; Z., D. (2026). Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines14102286
Vancouver
D A, Z. D. Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study. Biomedicines. 2026. doi:10.3390/biomedicines14102286.
BibTeX
@article{aygnejafari2026Senesc, title = {Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.}, author = {Aygüneş-Jafari D and Düzgün Z.}, journal = {Biomedicines}, year = {2026}, doi = {10.3390/biomedicines14102286}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings